Drug Trial Radar · NCT04655118
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
Last checked: Nov 19, 2026Latest source record: May 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
121
Planned (sponsor's estimate)
Start
Oct 22, 2020
Primary completion
Jun 30, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Telios Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis (Cohorts 1-3) or Indolent Systemic Mastocytosis (Cohort 5). Participants must be diagnosed with Myelofibrosis and be relapsed/refractory (e.g., having failed prior therapy), intolerant, or ineligible to receive JAKi treatment, or be diagnosed with Indolent Systemic Mastocytosis.
Conditions
- Myelofibrosis
- Indolent Systemic Mastocytosis
Interventions
TL-895Drug
TL-895 is an experimental tyrosine kinase inhibitor drug taken by mouth.
PlaceboDrug
Placebo to match TL-895
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohorts 1-3: Determine the RP2D of TL-895Time frame: 9 months
- Cohort 5: Determine the RP2D of TL-895Time frame: Week 24
Locations
52 sites in 13 countries. Site status is shown where the registry gives one.
University of Colorado - Aurora Cancer Center
Aurora, Colorado · Completed
Mayo Clinic - Rochester
Rochester, Minnesota · Recruiting
Gabrail Cancer Center
Canton, Ohio · Completed
University of Cincinnati (UC) Physicians Company, LLC
Cincinnati, Ohio · Active not recruiting
Ohio State University
Columbus, Ohio · Active not recruiting
University of Texas, MD Anderson Cancer Center
Houston, Texas · Recruiting
Border Medical Oncology
East Albury, Australia · Completed
Southern Oncology Specialists
Kogarah, Australia · Completed
Royal Perth Hospital
Perth, Australia · Recruiting
St Vincent's Hospital Sydney
Sydney, Australia · Recruiting
Chu De Liège
Liège, Belgium · Recruiting
Cliniques Universitaires Saint-Luc
Woluwe-Saint-Lambert, Belgium · Active not recruiting
Instituto de Estudos e Pesquisas Sao Lucas - IEP - Sao Lucas
São Paulo, Brazil · Completed
University Hospital "St Ivan Rilski"
Sofia, Bulgaria · Completed
Military Medical Academy
Sofia, Bulgaria · Active not recruiting
CH Le Mans
Le Mans, France · Active not recruiting
CHU de Nantes - Hôtel-Dieu
Nantes, France · Completed
CHU de Nice - Hopital L' Archet II
Nice, France · Completed
Universitaetsklinikum Carl Gustav Carus Dresden
Dresden, Germany · Recruiting
Marien Hospital Duesseldorf
Düsseldorf, Germany · Completed
Klinik fur Innere Medizin IV - Hamatologie/Onkologie, Universitatsklinikum Hall
Halle, Germany · Recruiting
Universitaetsklinikum Jena
Jena, Germany · Recruiting
Praxisklinik fur Hamatologie und Onkologie
Koblenz, Germany · Completed
Debreceni Egyetem Klinikai Kozpont
Debrecen, Hungary · Completed
Markhot Ferenc Oktatokorhaz es Rendelointezet
Eger, Hungary · Completed
Szabolcs-Szatmár-Bereg Megyei Önkormányzat Jósa András Oktatókórház Megyei-Városi Tüdőgondozó Intézete
Nyíregyháza, Hungary · Completed
Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz
Székesfehérvár, Hungary · Completed
Azienda Ospedaliero Universitaria Policlinico G. Rodolico-San Marco - Presidio Ospedaliero G. Rodolico
Catania, Italy · Active not recruiting
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori
Meldola, Italy · Active not recruiting
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano
Milan, Italy · Active not recruiting
ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy · Active not recruiting
Azienda Ospedaliero Universitaria Maggiore Della Carita'
Novara, Italy · Active not recruiting
Azienda Ospedaliera di Perugia-Ospedale S. Maria della Misericordia
Perugia, Italy · Active not recruiting
AUSL della Romagna-Ospedale S.Maria delle Croci
Ravenna, Italy · Active not recruiting
Grande Ospedale Metropolitano Bianchi Melacrino Morelli
Reggio Calabria, Italy · Active not recruiting
Azienda Ospedaliero Universitaria Policlinico Umberto I
Roma, Italy · Active not recruiting
Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy, Klinika Hematologi
Bydgoszcz, Poland · Active not recruiting
Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii
Gdansk, Poland · Active not recruiting
Klinika Hematologii Collegium Medicum Uniwersytetu Jagiellonskiego
Krakow, Poland · Not yet recruiting
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu, Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku
Wroclaw, Poland · Recruiting
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.